4.7 Review

Glycolysis as a target for the design of new anti-trypanosome drugs

Journal

DRUG RESISTANCE UPDATES
Volume 4, Issue 1, Pages 50-65

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1054/drup.2000.0177

Keywords

-

Funding

  1. NIAID NIH HHS [AI44199] Funding Source: Medline

Ask authors/readers for more resources

Glycolysis is perceived as a promising target for new drugs against parasitic trypanosomatid protozoa because this pathway plays an essential role in their ATP supply, Trypanosomatid glycolysis is unique in that it is compartmentalized, and many of its enzymes display unique structural and kinetic features. Structure- and catalytic mechanism-based approaches are applied to design compounds that inhibit the glycolytic enzymes of the parasites without affecting the corresponding proteins of the human host. For some trypanosomatid enzymes, potent and selective inhibitors have already been developed that affect only the growth of cultured trypanosomatids, and not mammalian cells. (C) 2001 Harcourt Publishers Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available